Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor

J. H. Schiller, P. L. Witt, B. Storer, D. Alberti, M. B. Tombes, R. Arzoomanian, R. R. Brown, R. A. Proctor, S. D. Voss, D. R. Spriggs, D. L. Trump, E. C. Borden

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Tumor necrosis factor (TNF) and gamma-interferon (γ-IFN) are cytokines with synergistic biologic and antiproliferative effects in vitro and in mouse models. The biologic effects of the combination of TNF and γ-IFN, however, have not been studied well in humans. A Phase I trial was conducted of TNF and γ-IFN therapy in 24 patients with advanced malignancies to determine the tolerability of the combination and the biologic effects of TNF and γ-IFN in vivo. Both TNF and γ-IFN were administered as 30-minute intravenous infusions three times per week. Doses of TNF ranged from 25 to 100 μg/m2; all patients received 100 μg/m2 of γ-IFN. Dose-limiting toxicity consisted primarily of orthostatic hypotension and constitutional symptoms. The maximum tolerated dose level (MTDL) of 50 μg/m2 of TNF and 100 μg/m2 IFN-γ was less than the maximum tolerated dose (MTD) observed in previous Phase I trials of γ-IFN and TNF alone. Biologic responses were studied in seven patients treated at the MTDL. Serum interleukin-2 receptor levels and neopterin secretion were enhanced significantly 24 hours after therapy (P = 0.002); enhancement of monocyte Fc receptor levels had borderline statistical significance (P = 0.07). With the exception of the mean fluorescent intensity on monocytes positive for histocompatibility antigen HLA-DR (P = 0.03), HLA Class I and II cell surface protein expression was not increased. The combination significantly enhanced indoleamine dioxygenase activity and serum β2-microglobulin expression (P < 0.04) but not 2',5'-oligoadenylate synthetase activity, bactericidal function, or chemiluminescence. These results were compared retrospectively with those observed in previous Phase I trials of γ-IFN and TNF alone. The combination of TNF and γ-IFN significantly increased urinary kynurenine levels more than either TNF alone or γ-IFN alone. Given the limitations inherent in any retrospective analysis, however, the enhancement in the other biologic parameters measured at the MTDL during this trial did not differ significantly from the changes observed at the MTD of either TNF or γ-IFN alone. It was concluded that the combination of TNF and γ-IFN, when administered at the MTDL of the combination, does not offer any enhancement in biologic responses over either agent alone.

Original languageEnglish (US)
Pages (from-to)562-571
Number of pages10
JournalCancer
Volume69
Issue number2
StatePublished - 1992

Fingerprint

Interferon-gamma
Tumor Necrosis Factor-alpha
Maximum Tolerated Dose
Therapeutics
Monocytes
2',5'-Oligoadenylate Synthetase
Kynurenine
Neopterin
Dioxygenases
Orthostatic Hypotension
Histocompatibility Antigens
Fc Receptors
Interleukin-2 Receptors
HLA-DR Antigens
Luminescence
Serum
Intravenous Infusions
Membrane Proteins
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schiller, J. H., Witt, P. L., Storer, B., Alberti, D., Tombes, M. B., Arzoomanian, R., ... Borden, E. C. (1992). Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer, 69(2), 562-571.

Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. / Schiller, J. H.; Witt, P. L.; Storer, B.; Alberti, D.; Tombes, M. B.; Arzoomanian, R.; Brown, R. R.; Proctor, R. A.; Voss, S. D.; Spriggs, D. R.; Trump, D. L.; Borden, E. C.

In: Cancer, Vol. 69, No. 2, 1992, p. 562-571.

Research output: Contribution to journalArticle

Schiller, JH, Witt, PL, Storer, B, Alberti, D, Tombes, MB, Arzoomanian, R, Brown, RR, Proctor, RA, Voss, SD, Spriggs, DR, Trump, DL & Borden, EC 1992, 'Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor', Cancer, vol. 69, no. 2, pp. 562-571.
Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R et al. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer. 1992;69(2):562-571.
Schiller, J. H. ; Witt, P. L. ; Storer, B. ; Alberti, D. ; Tombes, M. B. ; Arzoomanian, R. ; Brown, R. R. ; Proctor, R. A. ; Voss, S. D. ; Spriggs, D. R. ; Trump, D. L. ; Borden, E. C. / Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. In: Cancer. 1992 ; Vol. 69, No. 2. pp. 562-571.
@article{030237f578e2409ab2221c190498dbdf,
title = "Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor",
abstract = "Tumor necrosis factor (TNF) and gamma-interferon (γ-IFN) are cytokines with synergistic biologic and antiproliferative effects in vitro and in mouse models. The biologic effects of the combination of TNF and γ-IFN, however, have not been studied well in humans. A Phase I trial was conducted of TNF and γ-IFN therapy in 24 patients with advanced malignancies to determine the tolerability of the combination and the biologic effects of TNF and γ-IFN in vivo. Both TNF and γ-IFN were administered as 30-minute intravenous infusions three times per week. Doses of TNF ranged from 25 to 100 μg/m2; all patients received 100 μg/m2 of γ-IFN. Dose-limiting toxicity consisted primarily of orthostatic hypotension and constitutional symptoms. The maximum tolerated dose level (MTDL) of 50 μg/m2 of TNF and 100 μg/m2 IFN-γ was less than the maximum tolerated dose (MTD) observed in previous Phase I trials of γ-IFN and TNF alone. Biologic responses were studied in seven patients treated at the MTDL. Serum interleukin-2 receptor levels and neopterin secretion were enhanced significantly 24 hours after therapy (P = 0.002); enhancement of monocyte Fc receptor levels had borderline statistical significance (P = 0.07). With the exception of the mean fluorescent intensity on monocytes positive for histocompatibility antigen HLA-DR (P = 0.03), HLA Class I and II cell surface protein expression was not increased. The combination significantly enhanced indoleamine dioxygenase activity and serum β2-microglobulin expression (P < 0.04) but not 2',5'-oligoadenylate synthetase activity, bactericidal function, or chemiluminescence. These results were compared retrospectively with those observed in previous Phase I trials of γ-IFN and TNF alone. The combination of TNF and γ-IFN significantly increased urinary kynurenine levels more than either TNF alone or γ-IFN alone. Given the limitations inherent in any retrospective analysis, however, the enhancement in the other biologic parameters measured at the MTDL during this trial did not differ significantly from the changes observed at the MTD of either TNF or γ-IFN alone. It was concluded that the combination of TNF and γ-IFN, when administered at the MTDL of the combination, does not offer any enhancement in biologic responses over either agent alone.",
author = "Schiller, {J. H.} and Witt, {P. L.} and B. Storer and D. Alberti and Tombes, {M. B.} and R. Arzoomanian and Brown, {R. R.} and Proctor, {R. A.} and Voss, {S. D.} and Spriggs, {D. R.} and Trump, {D. L.} and Borden, {E. C.}",
year = "1992",
language = "English (US)",
volume = "69",
pages = "562--571",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor

AU - Schiller, J. H.

AU - Witt, P. L.

AU - Storer, B.

AU - Alberti, D.

AU - Tombes, M. B.

AU - Arzoomanian, R.

AU - Brown, R. R.

AU - Proctor, R. A.

AU - Voss, S. D.

AU - Spriggs, D. R.

AU - Trump, D. L.

AU - Borden, E. C.

PY - 1992

Y1 - 1992

N2 - Tumor necrosis factor (TNF) and gamma-interferon (γ-IFN) are cytokines with synergistic biologic and antiproliferative effects in vitro and in mouse models. The biologic effects of the combination of TNF and γ-IFN, however, have not been studied well in humans. A Phase I trial was conducted of TNF and γ-IFN therapy in 24 patients with advanced malignancies to determine the tolerability of the combination and the biologic effects of TNF and γ-IFN in vivo. Both TNF and γ-IFN were administered as 30-minute intravenous infusions three times per week. Doses of TNF ranged from 25 to 100 μg/m2; all patients received 100 μg/m2 of γ-IFN. Dose-limiting toxicity consisted primarily of orthostatic hypotension and constitutional symptoms. The maximum tolerated dose level (MTDL) of 50 μg/m2 of TNF and 100 μg/m2 IFN-γ was less than the maximum tolerated dose (MTD) observed in previous Phase I trials of γ-IFN and TNF alone. Biologic responses were studied in seven patients treated at the MTDL. Serum interleukin-2 receptor levels and neopterin secretion were enhanced significantly 24 hours after therapy (P = 0.002); enhancement of monocyte Fc receptor levels had borderline statistical significance (P = 0.07). With the exception of the mean fluorescent intensity on monocytes positive for histocompatibility antigen HLA-DR (P = 0.03), HLA Class I and II cell surface protein expression was not increased. The combination significantly enhanced indoleamine dioxygenase activity and serum β2-microglobulin expression (P < 0.04) but not 2',5'-oligoadenylate synthetase activity, bactericidal function, or chemiluminescence. These results were compared retrospectively with those observed in previous Phase I trials of γ-IFN and TNF alone. The combination of TNF and γ-IFN significantly increased urinary kynurenine levels more than either TNF alone or γ-IFN alone. Given the limitations inherent in any retrospective analysis, however, the enhancement in the other biologic parameters measured at the MTDL during this trial did not differ significantly from the changes observed at the MTD of either TNF or γ-IFN alone. It was concluded that the combination of TNF and γ-IFN, when administered at the MTDL of the combination, does not offer any enhancement in biologic responses over either agent alone.

AB - Tumor necrosis factor (TNF) and gamma-interferon (γ-IFN) are cytokines with synergistic biologic and antiproliferative effects in vitro and in mouse models. The biologic effects of the combination of TNF and γ-IFN, however, have not been studied well in humans. A Phase I trial was conducted of TNF and γ-IFN therapy in 24 patients with advanced malignancies to determine the tolerability of the combination and the biologic effects of TNF and γ-IFN in vivo. Both TNF and γ-IFN were administered as 30-minute intravenous infusions three times per week. Doses of TNF ranged from 25 to 100 μg/m2; all patients received 100 μg/m2 of γ-IFN. Dose-limiting toxicity consisted primarily of orthostatic hypotension and constitutional symptoms. The maximum tolerated dose level (MTDL) of 50 μg/m2 of TNF and 100 μg/m2 IFN-γ was less than the maximum tolerated dose (MTD) observed in previous Phase I trials of γ-IFN and TNF alone. Biologic responses were studied in seven patients treated at the MTDL. Serum interleukin-2 receptor levels and neopterin secretion were enhanced significantly 24 hours after therapy (P = 0.002); enhancement of monocyte Fc receptor levels had borderline statistical significance (P = 0.07). With the exception of the mean fluorescent intensity on monocytes positive for histocompatibility antigen HLA-DR (P = 0.03), HLA Class I and II cell surface protein expression was not increased. The combination significantly enhanced indoleamine dioxygenase activity and serum β2-microglobulin expression (P < 0.04) but not 2',5'-oligoadenylate synthetase activity, bactericidal function, or chemiluminescence. These results were compared retrospectively with those observed in previous Phase I trials of γ-IFN and TNF alone. The combination of TNF and γ-IFN significantly increased urinary kynurenine levels more than either TNF alone or γ-IFN alone. Given the limitations inherent in any retrospective analysis, however, the enhancement in the other biologic parameters measured at the MTDL during this trial did not differ significantly from the changes observed at the MTD of either TNF or γ-IFN alone. It was concluded that the combination of TNF and γ-IFN, when administered at the MTDL of the combination, does not offer any enhancement in biologic responses over either agent alone.

UR - http://www.scopus.com/inward/record.url?scp=0026602180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026602180&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 562

EP - 571

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -